Literature DB >> 1330298

Sensitivity of resistant human tumor cell lines to tumor necrosis factor and adriamycin used in combination: correlation between down-regulation of tumor necrosis factor-messenger RNA induction and overcoming resistance.

J T Safrit1, B Bonavida.   

Abstract

A number of human tumor cell lines of various histological origin were examined for their sensitivity and resistance to tumor necrosis factor-alpha (TNF) and Adriamycin (ADR). Six ovarian lines, and one each of a renal, lung, and B-cell line, were tested for putative mechanisms of resistance to these agents. Cytotoxicity resulting from TNF or ADR showed no overall correlation in these lines. The combination of TNF and ADR produced enhanced cytotoxicity against these tumor lines and furthermore resulted in overcoming the resistance of TNF or ADR alone or in combination. A proposed mechanism of TNF resistance in tumor cells is the endogenous production of TNF mRNA and protein. There was a positive correlation between resistance to TNF and the constitutive production of TNF mRNA and protein. The TNF-resistant lines that did not constitutively produce TNF mRNA and protein and the three TNF-sensitive tumor lines exhibited up-regulation of their TNF mRNA in the presence of TNF or phorbol myristate acetate/ionophore, but did not secrete any detectable protein. Due to the enhanced cytotoxicity seen with the combination of TNF and ADR, the effect of this combination on the level of TNF mRNA was examined. ADR alone reduced the constitutive level of TNF mRNA and in combination with TNF reduced the level of induction produced by TNF. This down-regulation of TNF mRNA by ADR may play a role in the enhanced cytotoxicity seen with the combination of these 2 agents.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1330298

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Sensitization of human malignant glioma cell lines to tumor necrosis factor-induced apoptosis by cisplatin.

Authors:  L Duan; M Aoyagi; M Tamaki; K Nakagawa; G Nagashima; Y Nagasaka; K Ohno; K Yamamoto; K Hirakawa
Journal:  J Neurooncol       Date:  2001-03       Impact factor: 4.130

Review 2.  Active vs. passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation: a hypothesis.

Authors:  D J Stewart; G P Raaphorst; J Yau; A R Beaubien
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

3.  Ebselen abrogates TNFalpha induced pro-inflammatory response in glioblastoma.

Authors:  Richa Tewari; Vivek Sharma; Nitin Koul; Abhishek Ghosh; Christy Joseph; Ugir Hossain Sk; Ellora Sen
Journal:  Mol Oncol       Date:  2008-11-05       Impact factor: 6.603

Review 4.  Human cell lines as models for multidrug resistance in solid tumours.

Authors:  M Clynes; M Heenan; K Hall
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

5.  Effect of tumor necrosis factor-alpha and interferon-gamma on the growth of human prostate cancer cell lines.

Authors:  Y Nakajima; A DelliPizzi; C Mallouh; N R Ferreri
Journal:  Urol Res       Date:  1995

6.  Inhibition of Casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNFα)-induced apoptosis through SIRT1 inhibition.

Authors:  D Dixit; V Sharma; S Ghosh; V S Mehta; E Sen
Journal:  Cell Death Dis       Date:  2012-02-09       Impact factor: 8.469

7.  Reversal of tumor necrosis factor resistance in tumor cells by adriamycin via suppression of intracellular resistance factors.

Authors:  N Watanabe; T Okamoto; N Tsuji; H Sasaki; S Akiyama; D Kobayashi; T Sato; N Yamauchi; Y Niitsu
Journal:  Jpn J Cancer Res       Date:  1995-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.